Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
BUSINESS
Ono Kicks Off Japan Clinical Study for Pancreatitis Med Foipan for COVID-19
Ono Pharmaceutical said on June 5 that it has launched a clinical trial in Japan to gauge the efficacy of its pancreatitis drug Foipan Tablets (camostat mesilate) for the treatment of COVID-19. Dosing in healthy adults will start shortly, and…
To read the full story
Related Article
- Ono to Ditch Foipan Development for COVID-19 as it Misses Goal in Japan PIII
June 14, 2021
- Ono Launches Japan PIII Study for Foipan for COVID-19
November 10, 2020
- Ono Drops ONO-5334 for COVID-19, Pursues Foipan Project
July 31, 2020
- Ono to Test Pancreatitis Med Foipan for COVID-19: President
May 13, 2020
- Ono’s FY2019 Sales Up 1.3% on Keytruda-Tied Royalties
May 13, 2020
- Ono Curbing Camostat Supplies after Drug Reported as Potential COVID-19 Hopeful
April 15, 2020
BUSINESS
- Fuso Grabs Japan Rights to Dimerix’s Kidney Disease Drug
January 8, 2025
- Mitsubishi Tanabe Gets Taiwan Rights for Rigel/Kissei’s ITP Drug
January 8, 2025
- Daiichi Sankyo to Transfer Avastin Biosimilar to Amgen in Japan
January 8, 2025
- BMS Taps Ex-Lilly Exec Katsuma as Japan Chief, Sugino as Asia-Pacific GM
January 7, 2025
- Biogen Japan Chief Hopes to Build Momentum in ALS Space Riding on Success with Qalsody
January 7, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…